Neurocrine Biosciences Statistics
Share Statistics
Neurocrine Biosciences has 99.7M
shares outstanding. The number of shares has increased by -0.93%
in one year.
| Shares Outstanding | 99.7M |
| Shares Change (YoY) | -0.93% |
| Shares Change (QoQ) | -1.52% |
| Owned by Institutions (%) | 93.98% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 716 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 4.37M, so 4.38% of the outstanding
shares have been sold short.
| Short Interest | 4.37M |
| Short % of Shares Out | 4.38% |
| Short % of Float | 5.14% |
| Short Ratio (days to cover) | 2.27 |
Valuation Ratios
The PE ratio is 40.15 and the forward
PE ratio is 19.6.
Neurocrine Biosciences's PEG ratio is
1.22.
| PE Ratio | 40.15 |
| Forward PE | 19.6 |
| PS Ratio | 5.82 |
| Forward PS | 2.7 |
| PB Ratio | 5.29 |
| P/FCF Ratio | 24.6 |
| PEG Ratio | 1.22 |
Financial Ratio HistoryEnterprise Valuation
Neurocrine Biosciences has an Enterprise Value (EV) of 13.93B.
| EV / Sales | 5.91 |
| EV / EBITDA | 21.77 |
| EV / EBIT | 23.39 |
| EV / FCF | 24.99 |
Financial Position
The company has a current ratio of 3.4,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.4 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 0.71 |
| Debt / FCF | 0.82 |
| Interest Coverage | 4.51 |
Financial Efficiency
Return on Equity is 13.18% and Return on Invested Capital is 12.48%.
| Return on Equity | 13.18% |
| Return on Assets | 9.18% |
| Return on Invested Capital | 12.48% |
| Revenue Per Employee | $1,308,500 |
| Profits Per Employee | $189,611.11 |
| Employee Count | 1,800 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.59 |
Taxes
| Income Tax | 144.7M |
| Effective Tax Rate | 29.77% |
Stock Price Statistics
The stock price has increased by -15.8% in the
last 52 weeks. The beta is 0.26, so Neurocrine Biosciences's
price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | -15.8% |
| 50-Day Moving Average | 107.51 |
| 200-Day Moving Average | 124.61 |
| Relative Strength Index (RSI) | 64.22 |
| Average Volume (20 Days) | 1,609,254 |
Income Statement
In the last 12 months, Neurocrine Biosciences had revenue of 2.36B
and earned 341.3M
in profits. Earnings per share was 3.4.
| Revenue | 2.36B |
| Gross Profit | 2.32B |
| Operating Income | 570.5M |
| Net Income | 341.3M |
| EBITDA | 639.7M |
| EBIT | 612.6M |
| Earnings Per Share (EPS) | 3.4 |
Full Income StatementBalance Sheet
The company has 233M in cash and 455.1M in
debt, giving a net cash position of -222.1M.
| Cash & Cash Equivalents | 233M |
| Total Debt | 455.1M |
| Net Cash | -222.1M |
| Retained Earnings | 29.2M |
| Total Assets | 3.72B |
| Working Capital | 1.22B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 595.4M
and capital expenditures -38.2M, giving a free cash flow of 557.2M.
| Operating Cash Flow | 595.4M |
| Capital Expenditures | -38.2M |
| Free Cash Flow | 557.2M |
| FCF Per Share | 5.55 |
Full Cash Flow StatementMargins
Gross margin is 98.56%, with operating and profit margins of 24.22% and 14.49%.
| Gross Margin | 98.56% |
| Operating Margin | 24.22% |
| Pretax Margin | 20.63% |
| Profit Margin | 14.49% |
| EBITDA Margin | 27.16% |
| EBIT Margin | 24.22% |
| FCF Margin | 23.66% |
